Pfizer and BioNTech portion first patients in US Covid-19 antibody preliminary

Pfizer and BioNTech portion first patients in US Covid-19 antibody preliminary 
Pfizer and BioNTech have reported the dosing of the main members of its US Stage I/II Covid-19 antibody study. The pair has four antibody competitors against the novel coronavirus in the BNT162 improvement program; an investigation of these items are as of now in progress in Germany. 
Pfizer administrator and President Albert Bourla stated: "With our extraordinary and powerful clinical examination program in progress, beginning in Europe and now the US we anticipate progressing rapidly and cooperatively with our accomplices at BioNTech and administrative specialists to carry a protected and useful immunization to the patients who need it most. 
"The short, under four-month time period in which we've had the option to move from pre-clinical investigations to human testing is remarkable and further shows our pledge to committing our top tier assets, from the lab to assembling and past, in the fight against Covid-19."